The Impact of Proactive Gastrostomy Tube Placement on Treatment-related Outcomes in Young Children With High-grade Central Nervous System Tumors

• Published in: Journal of pediatric hematology/oncology Vol. 45; no. 6; pp. 333 - 338
• Main Authors: Kotch, Chelsea, Elgarten, Caitlin W., McWhorter, Jessica, Schmus, Cynthia, Wilhelm, Darielle, Li, Yimei, Minturn, Jane E.
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 01-08-2023
• Subjects: Central Nervous System Neoplasms - therapy; Child; Child, Preschool; Enteral Nutrition; Gastrostomy; Humans; Retrospective Studies; Treatment Outcome
• DOI: 10.1097/MPH.0000000000002694
• EISSN: 1536-3678
• ISSN: 1077-4114

Young children undergoing treatment with intensive chemotherapy for high-grade central nervous system (CNS) tumors are at risk for malnutrition, yet no guidelines exist for the placement of enteral tubes. Prior studies evaluated the impact of proactive gastrostomy tube (GT) placement with a narrow scope of outcomes, such as weight. To examine the impact of proactive GT on comprehensive treatment outcomes, we performed a single-center, retrospective study of children younger than 60 months of age with high-grade CNS tumors treated per CCG99703 or ACNS0334 between 2015 and 2022. Of 26 patients included, 9 (35%) underwent proactive GT, 8 (30%) had rescue GT, and 9 (35%) had a nasogastric tube (NGT). Clinically significant weight loss occurred in 47% of patients with NGT during induction compared with 22% with proactive GT (
P
= 0.274); however, between cohorts, there was no significant difference in antibiotic or parenteral nutrition utilization, weight loss at therapy completion, and duration of hospitalization. Therefore, proactive GT placement was modestly effective at preventing significant weight loss during induction, however, there was no clear benefit for hospitalization duration, antibiotic, or parental nutrition requirements compared with NGT. We recommend an individualized approach to GT placement for young children with CNS malignancies undergoing intensive chemotherapy.